Abstract: The disclosure concerns a method of treating complications of acute or chronic hyperglycemia and/or diet-induced obesity comprising: (i) determining whether a patient suffers from complications related to acute or chronic hyperglycemia and/or diet induced obesity, and if so, (ii) administering to the patient in need thereof a selective inhibitor of soluble TNF-? but not transmembrane TNF-?. For purposes herein, complications of acute or chronic hyperglycemia and/or diet-induced obesity include: diabetes mellitus, insulin resistance, hepatic steatosis, non-alcoholic hepatic steatosis, fibrotic liver disease, vascular disease, and chronic intestinal inflammation.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
October 24, 2023
Assignees:
INmune Bio Inc, EMORY UNIVERSITY
Inventors:
Maria Elizabeth De Souza Rodrigues, Maria de Lourdes Gamez Tansey, Christopher J. Barnum, Raymond J. Tesi, Dean P. Jones, Douglas I. Walker
Abstract: A method of treating non-alcoholic steatohepatitis (NASH) in a subject includes administering to the subject a therapeutically effective amount of a selective inhibitor of solTNF-?, whereby the subject is treated. In some embodiments, the selective inhibitor of solTNF-? includes a DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein. In some embodiments, the DN-TNF-? protein includes XPRO1595.
Abstract: The disclosure concerns a method of treating complications of acute or chronic hyperglycemia and/or diet-induced obesity comprising: (i) determining whether a patient suffers from complications related to acute or chronic hyperglycemia and/or diet induced obesity, and if so, (ii) administering to the patient in need thereof a selective inhibitor of soluble TNF-? but not transmembrane TNF-?. For purposes herein, complications of acute or chronic hyperglycemia and/or diet-induced obesity include: diabetes mellitus, insulin resistance, hepatic steatosis, non-alcoholic hepatic steatosis, fibrotic liver disease, vascular disease, and chronic intestinal inflammation.
Type:
Application
Filed:
September 27, 2018
Publication date:
September 17, 2020
Applicants:
INmune Bio, Inc., EMORY UNIVERSITY
Inventors:
Maria Elizabeth DE SOUZA RODRIGUES, Malu G. TANSEY, Christopher J. BARNUM, Raymond J. TESI